6.
Krammer F, Pica N, Hai R, Margine I, Palese P
. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013; 87(12):6542-50.
PMC: 3676110.
DOI: 10.1128/JVI.00641-13.
View
7.
Ofek G, Guenaga F, Schief W, Skinner J, Baker D, Wyatt R
. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A. 2010; 107(42):17880-7.
PMC: 2964213.
DOI: 10.1073/pnas.1004728107.
View
8.
Caradonna T, Ronsard L, Yousif A, Windsor I, Hecht R, Bracamonte-Moreno T
. An epitope-enriched immunogen expands responses to a conserved viral site. Cell Rep. 2022; 41(6):111628.
PMC: 9883670.
DOI: 10.1016/j.celrep.2022.111628.
View
9.
Feldman J, Bals J, Altomare C, St Denis K, Lam E, Hauser B
. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Sci Immunol. 2021; 6(66):eabl5842.
PMC: 8720485.
DOI: 10.1126/sciimmunol.abl5842.
View
10.
McLellan J, Chen M, Joyce M, Sastry M, Stewart-Jones G, Yang Y
. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342(6158):592-8.
PMC: 4461862.
DOI: 10.1126/science.1243283.
View
11.
Pallesen J, Wang N, Corbett K, Wrapp D, Kirchdoerfer R, Turner H
. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114(35):E7348-E7357.
PMC: 5584442.
DOI: 10.1073/pnas.1707304114.
View
12.
Moore M, Dorfman T, Li W, Wong S, Li Y, Kuhn J
. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol. 2004; 78(19):10628-35.
PMC: 516384.
DOI: 10.1128/JVI.78.19.10628-10635.2004.
View
13.
Shinnakasu R, Sakakibara S, Yamamoto H, Wang P, Moriyama S, Sax N
. Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. J Exp Med. 2021; 218(12).
PMC: 8641255.
DOI: 10.1084/jem.20211003.
View
14.
Wheatley A, Fox A, Tan H, Juno J, Davenport M, Subbarao K
. Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 2021; 42(11):956-959.
PMC: 8440232.
DOI: 10.1016/j.it.2021.09.001.
View
15.
Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H
. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March.... MMWR Morb Mortal Wkly Rep. 2021; 70(34):1163-1166.
PMC: 8389386.
DOI: 10.15585/mmwr.mm7034e3.
View
16.
Caradonna T, Schmidt A
. Protein engineering strategies for rational immunogen design. NPJ Vaccines. 2021; 6(1):154.
PMC: 8683408.
DOI: 10.1038/s41541-021-00417-1.
View
17.
Walls A, Fiala B, Schafer A, Wrenn S, Pham M, Murphy M
. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020; 183(5):1367-1382.e17.
PMC: 7604136.
DOI: 10.1016/j.cell.2020.10.043.
View
18.
Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K
. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670.
PMC: 9531318.
DOI: 10.1038/s41586-021-04386-2.
View
19.
Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R
. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571.
PMC: 7581537.
DOI: 10.1038/s41586-020-2622-0.
View
20.
MacDonald J, Maksimiak K, Sadowski M, Taylor W
. De novo backbone scaffolds for protein design. Proteins. 2009; 78(5):1311-25.
PMC: 2841848.
DOI: 10.1002/prot.22651.
View